QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
NASDAQ:INCY

Incyte - INCY Stock Forecast, Price & News

$85.70
-0.31 (-0.36%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$85.42
$86.08
50-Day Range
$77.45
$86.01
52-Week Range
$65.07
$86.29
Volume
931,526 shs
Average Volume
1.88 million shs
Market Capitalization
$19.07 billion
P/E Ratio
21.81
Dividend Yield
N/A
Price Target
$78.75

Incyte MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
8.1% Downside
$78.75 Price Target
Short Interest
Healthy
1.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
0.49mentions of Incyte in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$3.77 M Sold Last Quarter
Proj. Earnings Growth
56.07%
From $2.14 to $3.34 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

186th out of 1,055 stocks

Commercial Physical Research Industry

4th out of 17 stocks


INCY stock logo

About Incyte (NASDAQ:INCY) Stock

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Stock News Headlines

Incyte: Opzelura Is The Main Growth Driver
Incyte Co. (NASDAQ:INCY) Sees Large Decline in Short Interest
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Incyte: Making Hay While The Sun Shines
Incyte Gets a Quantitative Upgrade
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Incyte A Buy As Revenue From Opzelura Ramps
Is Incyte Building a Vitiligo Empire? - TheStreet
See More Headlines
Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Company Calendar

Last Earnings
11/01/2022
Today
1/27/2023
Next Earnings (Confirmed)
2/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INCY
CUSIP
45337C10
Employees
2,094
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$78.75
High Stock Price Forecast
$98.00
Low Stock Price Forecast
$63.00
Forecasted Upside/Downside
-8.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
7 Analysts

Profitability

Net Income
$948.58 million
Pretax Margin
17.07%

Debt

Sales & Book Value

Annual Sales
$2.99 billion
Cash Flow
$2.40 per share
Book Value
$17.07 per share

Miscellaneous

Free Float
183,542,000
Market Cap
$19.07 billion
Optionable
Optionable
Beta
0.70

Social Links


Key Executives

  • Herve HoppenotHerve Hoppenot
    Chairman, President & Chief Executive Officer
  • Christiana Stamoulis
    Chief Financial Officer & Executive Vice President
  • Steven H. SteinSteven H. Stein
    Chief Medical Officer & Executive Vice President
  • Dashyant DhanakDashyant Dhanak
    Chief Scientific Officer & Executive VP
  • Barry FlannellyBarry Flannelly
    EVP & General Manager-North America













INCY Stock - Frequently Asked Questions

Should I buy or sell Incyte stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings
or view top-rated stocks.

What is Incyte's stock price forecast for 2023?

7 brokerages have issued 1-year price targets for Incyte's shares. Their INCY share price forecasts range from $63.00 to $98.00. On average, they expect the company's stock price to reach $78.75 in the next twelve months. This suggests that the stock has a possible downside of 8.4%.
View analysts price targets for INCY
or view top-rated stocks among Wall Street analysts.

How have INCY shares performed in 2023?

Incyte's stock was trading at $80.32 at the beginning of 2023. Since then, INCY shares have increased by 7.1% and is now trading at $86.01.
View the best growth stocks for 2023 here
.

When is Incyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023.
View our INCY earnings forecast
.

How can I listen to Incyte's earnings call?

Incyte will be holding an earnings conference call on Tuesday, February 7th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13735569".

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) posted its earnings results on Tuesday, November, 1st. The biopharmaceutical company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.54 by $0.10. The biopharmaceutical company earned $823.30 million during the quarter, compared to analysts' expectations of $847 million. Incyte had a trailing twelve-month return on equity of 9.04% and a net margin of 26.30%.

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by a variety of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.50%), ARK Investment Management LLC (0.43%), Country Trust Bank (0.21%), Allspring Global Investments Holdings LLC (0.20%), Grimes & Company Inc. (0.09%) and National Bank of Canada FI (0.05%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Maria E Pasquale, Michael James Morrissey, Paul Trower, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends
.

How do I buy shares of Incyte?

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $86.01.

How much money does Incyte make?

Incyte (NASDAQ:INCY) has a market capitalization of $19.14 billion and generates $2.99 billion in revenue each year. The biopharmaceutical company earns $948.58 million in net income (profit) each year or $3.93 on an earnings per share basis.

How many employees does Incyte have?

The company employs 2,094 workers across the globe.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The official website for the company is www.incyte.com. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at mbooth@incyte.com, or via fax at 302-425-2750.

This page (NASDAQ:INCY) was last updated on 1/27/2023 by MarketBeat.com Staff